

Jon Watts
410 posts

@jwattsgroup
Oligonucleotide Therapeutics and Chemical Biology. Find us also at @jwattsgroup.bsky.social








ReNAgade Therapeutics is acquired by RNA rival Orna Therapeutics a year after launching with $300M. The combined startup will focus on in vivo CAR-T cells and an in vivo gene editing therapy for sickle cell disease. More details in my story for @endpts endpts.com/renagade-is-ac…






In the latest paper from senior PhD student @Samantha_Sarli, we compare the activity profile of conjugated and unconjugated ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo. Amphiphilic lipids help drive safe uptake! Online now at NAR: academic.oup.com/nar/article/do…







"A Fluorescent Reporter Mouse for In Vivo Assessment of Genome Editing with Diverse Cas Nucleases and Prime Editors" Chen et al. liebertpub.com/doi/10.1089/cr…

